NASDAQ:ASBP Aspire Biopharma Q4 2025 Earnings Report $8.88 +0.10 (+1.14%) Closing price 10/5/2026 04:00 PM EasternExtended Trading$8.95 +0.07 (+0.79%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aspire Biopharma EPS ResultsActual EPS-$1.65Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAspire Biopharma Revenue ResultsActual Revenue$0.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAspire Biopharma Announcement DetailsQuarterQ4 2025Date3/30/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Aspire Biopharma Earnings HeadlinesAnalyzing Patrick Industries (NASDAQ:PATK) & Aspire Biopharma (NASDAQ:ASBP)15 minutes ago | americanbankingnews.comComparing Aspire Biopharma (NASDAQ:ASBP) and Aptiv (NYSE:APTV)September 29, 2026 | americanbankingnews.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Aspire-Lakewood Launches $10 Million Share Repurchase ProgramSeptember 9, 2026 | tipranks.comAspire Biopharma Holdings, Inc.: Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase ProgramSeptember 9, 2026 | finanznachrichten.deAspire Biopharma Changes Name to Aspire-Lakewood Holdings Inc.September 8, 2026 | usatoday.comSee More Aspire Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aspire Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aspire Biopharma and other key companies, straight to your email. Email Address About Aspire BiopharmaAspire Biopharma (NASDAQ:ASBP), Inc. is a clinical-stage biopharmaceutical company developing drug-delivery products based on proprietary oral thin-film technology. Its platform is designed to deliver medication through the mouth without requiring water or conventional swallowing, with the goal of enabling rapid absorption and improving ease of use. The company’s lead development program is an orally administered aspirin product intended for potential use in acute cardiovascular situations, where rapid delivery may be important. Aspire Biopharma is also evaluating additional applications of its delivery platform for other pharmaceutical compounds and therapeutic areas. The company’s products remain under development and require regulatory review and approval before they can be marketed. Aspire Biopharma became a publicly traded company following a business combination with PowerUp Acquisition Corp. in 2024.View Aspire Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
